Homoharringtonine as a Rapid SARS-CoV-2 Inhibitor: Molecular Insights

Study Background and Research Question

Homoharringtonine, a cytotoxic alkaloid originally derived from Cephalotaxus hainanensis, has been extensively studied as a protein synthesis inhibitor in cancer biology, particularly in the context of leukemia research. Its ability to bind to the eukaryotic 80S ribosome and interrupt protein chain elongation underpins its cytostatic effects and therapeutic value in hematologic malignancies. However, the COVID-19 pandemic prompted a re-examination of molecules with established clinical safety records and mechanistic overlap with viral replication pathways. The reference study (Wen et al., 2025) was driven by the urgent need for rapid, scalable antiviral interventions that could be deployed early in coronavirus outbreaks, focusing on whether homoharringtonine could serve as a first-line defense by targeting SARS-CoV-2 replication in the upper respiratory tract.

Key Innovation from the Reference Study

The central innovation of the reference study lies in demonstrating, with molecular and translational rigor, that homoharringtonine can rapidly and robustly clear SARS-CoV-2 infection through direct inhibition of viral protein synthesis. While its anti-leukemic properties are well established, the study extends its utility by showing that low nanomolar concentrations of homoharringtonine potently suppress replication of multiple coronaviruses in vitro. This positions homoharringtonine as a broad-spectrum antiviral, with the potential for rapid deployment in the early stages of future respiratory coronavirus epidemics. The authors also pioneer a practical delivery route—nasal spray or nebulization—for targeted, localized treatment of upper respiratory tract infection.

Methods and Experimental Design Insights

The research integrates multi-level experimental approaches, combining in vitro cell culture assays, animal models, and pilot clinical studies. In vitro, the antiviral potency of homoharringtonine was quantified against four distinct coronaviruses, including SARS-CoV-2, using plaque reduction and viral RNA quantification assays. Nanomolar concentrations were sufficient to inhibit viral replication, correlating with its established mechanism as a protein synthesis inhibitor.

In vivo, a mouse model of SARS-CoV-2 infection was used to test the efficacy of daily nasal administration of homoharringtonine (40 μg per day). The study monitored viral clearance from the upper respiratory tract over three days using RT-PCR.

Human data were generated from two small-scale clinical interventions. First, 26 cancer patients with COVID-19 received 1 mg/day homoharringtonine via nebulization; viral load was measured six hours post-administration. Second, 11 otherwise healthy patients were treated with repeated nasal sprays (0.2 mg daily), with virological endpoints assessed over a 2–4 day period.

Core Findings and Why They Matter

The major findings are both quantitative and mechanistic:

• Rapid viral clearance in animal models: All treated mice showed complete SARS-CoV-2 clearance from the upper respiratory tract within 3 days, compared to persistent infection in untreated controls (Wen et al., 2025).
• Clinical reduction of viral load: In cancer patients, a single nebulization reduced viral load by ~75% within six hours. In otherwise healthy patients, 10 out of 11 cleared the virus within 2–4 days, a significantly shorter duration than the typical 7–9 days observed during the same epidemic wave in China.
• No observed adverse effects: Both delivery routes (nebulization and nasal spray) were well tolerated in the observed cohorts.
• Mechanistic confirmation: The inhibition of viral replication was directly linked to homoharringtonine’s disruption of viral protein synthesis via eukaryotic 80S ribosome binding, matching its mode of action in oncology.

These results suggest that homoharringtonine could be rapidly repurposed as a first-line, locally administered antiviral for future respiratory coronavirus outbreaks, particularly during the early phase when viral replication in the upper respiratory tract drives transmission.

Comparison with Existing Internal Articles

Insights from internal literature reinforce and contextualize these findings. For instance, the article "Homoharringtonine Rapidly Clears SARS-CoV-2: Molecular Evidence" similarly reports rapid antiviral action in both animal and clinical settings, emphasizing the strategic importance of protocol optimization and delivery route. Another review, "Redefining Cancer and Antiviral Research Frontiers", highlights the dual-domain relevance of homoharringtonine, underlining its validated role in leukemia models and its emerging utility in SARS-CoV-2 antiviral research. These internal resources provide further context on workflow design, mechanistic specificity, and translational prospects, supporting the cross-domain application documented in the reference study. Researchers interested in the detailed mechanistic blueprint and translational perspectives may also consult this mechanistic review.

Limitations and Transferability

Despite promising results, several limitations should be noted. The clinical data, while striking, are derived from small, non-randomized cohorts; broader, controlled trials are needed to confirm efficacy and safety across diverse populations. The rapid clearance observed in animal models may not directly extrapolate to all human disease states, especially those with lower viral loads or different host responses. Furthermore, the safety profile of repeated nasal or nebulized administration in immunocompetent, non-cancer populations requires further study. Viral resistance and long-term effects on local mucosal immunity remain open questions. Finally, the translational leap from oncology to infectious disease, while mechanistically justified, necessitates careful protocol adaptation and regulatory consideration.

Why this cross-domain matters, maturity, and limitations

The repurposing of homoharringtonine from cancer biology to SARS-CoV-2 antiviral research is significant because it leverages a well-characterized cytotoxic agent and protein synthesis inhibitor with known pharmacodynamics and safety data. This cross-domain strategy accelerates the translational pipeline and provides an evidence-based platform for rapid response in future outbreaks. However, the maturity of this approach is contingent on further clinical validation and real-world scalability. Current evidence supports its use as an experimental intervention or in research settings, rather than as a population-wide prophylactic.

Protocol Parameters

• In vitro viral inhibition: Homoharringtonine demonstrates potent suppression of SARS-CoV-2 and other coronaviruses at nanomolar concentrations, consistent with its role as a protein synthesis inhibitor (Wen et al., 2025).
• Animal model administration: Daily nasal dripping of 40 μg homoharringtonine for 3 days achieved complete viral clearance in mice. Suitable for studies modeling early upper respiratory tract infection.
• Clinical intervention: Nebulization of 1 mg/day or repeated nasal spray totaling 0.2 mg/day showed rapid reduction in viral load in pilot patient cohorts. Optimal for exploratory studies and safety profiling in humans.
• Storage and handling: Homoharringtonine should be stored at -20°C; it is insoluble in water, but highly soluble in DMSO and ethanol (product information).
• Research workflow recommendation: When modeling cross-domain antiviral and oncology workflows, ensure compatibility with protein synthesis inhibition endpoints and cell cycle G1 phase arrest analysis.

Research Support Resources

Researchers aiming to replicate or extend these findings can access high-purity homoharringtonine (SKU N1504) for experimental workflows via APExBIO. This reagent enables precise modeling of protein synthesis inhibition, cell cycle arrest, and viral clearance in both cancer and infectious disease research. As always, homoharringtonine is intended strictly for scientific research use and should be handled following cytotoxic agent safety protocols.